Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | NAAA | Q02083 | 1/20 | 0.58 |
| ▸ | DGKA | P23743 | 1/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 2/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | PAM | P19021 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3822217 | 1.00 | HTR2C (1.00) | HTR2CNAAADGKAPRSS1PRSS2 | |
| Hexaminolevulinate SCHEMBL1070663 | 1.00 | HTR2C (1.00) | HTR2CNAAADGKAPRSS1PRSS2 | |
| SCHEMBL3829077 | 1.00 | HTR2C (1.00) | HTR2CNAAADGKAPRSS1PRSS2 | |
| SCHEMBL3822297 | 1.00 | HTR2C (1.00) | HTR2CNAAADGKAPRSS1PRSS2 | |
| SCHEMBL3824698 | 1.00 | HTR2C (1.00) | HTR2CNAAADGKAPRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL1613827 | 0.98 | HTR2C (0.97) | HTR2CNAAADGKAPRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL1613756 | 0.98 | HTR2C (0.97) | HTR2CNAAADGKAPRSS1PRSS2 | |
| Hexaminolevulinate SCHEMBL937621 | 0.98 | HTR2C (0.97) | HTR2CNAAADGKAPRSS1PRSS2 | |
| SCHEMBL987595 | 0.98 | HTR2C (0.96) | HTR2CNAAADGKAPRSS1PRSS2 | |
| SCHEMBL987461 | 0.93 | HTR2C (0.86) | HTR2CNAAADGKAPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539285-B2 | Therapeutic agent for hypertrophic cardiomyopathy | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2026-02-03 | — | — | US | disclosed |
| US-20240082189-A1 | THERAPEUTIC AGENT FOR HYPERTROPHIC CARDIOMYOPATHY | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2024-03-14 | — | — | US | disclosed |
| EP-4309651-A1 | THERAPEUTIC AGENT FOR HYPERTROPHIC CARDIOMYOPATHY | Juntendo Educational Foundation (JP) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022158591-A1 | THERAPEUTIC AGENT FOR HYPERTROPHIC CARDIOMYOPATHY | 学校法人順天堂 | 2022-07-28 | — | — | WO | disclosed |
| EP-0995448-B1 | COMPOUND FOR DIAGNOSING MALIGNANT TUMORS | SBI ALAPROMO CO LTD (JP) | 2009-09-02 | — | — | EP | disclosed |
| US-7135162-B2 | Agent for diagnosing and treating malignant tumors | COSMO RESEARCH INSTITUTE (JP) | 2006-11-14 | — | — | US | disclosed |
| US-6905671-B1 | Diagnostic agents and remedies for malignant tumors | COSMO RESEARCH INSTITUTE (JP) | 2005-06-14 | — | — | US | disclosed |
| US-20030065029-A1 | Agent for diagnosing and treating malignant tumors | COSMO RESEARCH INSTITUTE, COSMO OIL CO., LTD. | 2003-04-03 | — | — | US | disclosed |
| EP-0995448-A1 | DIAGNOSTIC AGENTS AND REMEDIES FOR MALIGNANT TUMORS | Cosmo Research Institute (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539285-B2 | Therapeutic agent for hypertrophic cardiomyopathy | ALAD, TNNT2, MYH2 | HTR2C 1207/4885NAAA 2337/4885DGKA 4071/4885 |
| US-20030065029-A1 | Agent for diagnosing and treating malignant tumors | ALAD, VHL, AADAT | HTR2C 2838/4885NAAA 180/4885DGKA 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.